ストックスクリーナーアプリを入手
5.4565
0.82%
-0.0235
前日終値:
$5.48
開ける：
$5.545
24時間の取引高:
10.45M
Relative Volume:
0.38
時価総額：
$2.18B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.5203
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
-8.66%
1か月 パフォーマンス:
+10.24%
6か月 パフォーマンス:
-27.44%
1年 パフォーマンス:
-14.68%
1日の値動き範囲:
$5.40
$5.69
1週間の範囲:
$5.28
$5.96
52週間の値動き範囲:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.45 | 2.40B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.41 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.53 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.73 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.97 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.01 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - Yahoo Finance
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - MSN
Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest
Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest
Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest
Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga
Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com
Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com
Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest
Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Recursion Reports Q2 Financial Results, Deploys Advanced Models for Medicine Discovery. - AInvest
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN
Recursion Pharmaceuticals Earnings Preview - 富途牛牛
Recursion Pharmaceuticals Q2 2025 Earnings: A TechBio Inflection Point? - AInvest
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Maximize portfolio growth with professional advice - Jammu Links News
Why is Recursion Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - Jammu Links News
How does Recursion Pharmaceuticals Inc. generate profit in a changing economyFree Predictions - Jammu Links News
Does Recursion Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on emerging investment opportunities - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
What makes Recursion Pharmaceuticals Inc. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockDiscover hidden gems in the stock market - Jammu Links News
When is Recursion Pharmaceuticals Inc. stock expected to show significant growthExplosive earning power - Jammu Links News
What institutional investors are buying Recursion Pharmaceuticals Inc. stockHigh-octane gains - Jammu Links News
Should I hold or sell Recursion Pharmaceuticals Inc. stock in 2025Outstanding growth strategies - Jammu Links News
What analysts say about Recursion Pharmaceuticals Inc. stockTremendous return rates - Jammu Links News
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month - Yahoo Finance
What are the latest earnings results for Recursion Pharmaceuticals Inc.Market Forecast Alerts Backed By Experts - jammulinksnews.com
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
0.38%
0.23%
大文字化:
|
ボリューム (24 時間):